HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM) Short Interest Down 13.7% in March

HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM) saw a large decline in short interest in March. As of March 13th, there was short interest totaling 278,317 shares, a decline of 13.7% from the February 26th total of 322,619 shares. Based on an average daily trading volume, of 27,811 shares, the days-to-cover ratio is currently 10.0 days. Currently, 0.2% of the shares of the stock are sold short.

HUTCHMED Trading Up 1.2%

HCM stock opened at $15.14 on Thursday. The company has a debt-to-equity ratio of 0.05, a current ratio of 4.96 and a quick ratio of 4.83. The company’s fifty day moving average price is $14.57 and its 200-day moving average price is $14.77. HUTCHMED has a one year low of $11.51 and a one year high of $19.50.

HUTCHMED (NASDAQ:HCM) last posted its earnings results on Friday, March 6th. The company reported $0.01 earnings per share for the quarter, missing the consensus estimate of $2.50 by ($2.49). The company had revenue of $135.42 million for the quarter, compared to the consensus estimate of $290.50 million. Research analysts forecast that HUTCHMED will post 0.16 EPS for the current year.

Analysts Set New Price Targets

HCM has been the subject of several recent analyst reports. Bank of America dropped their target price on shares of HUTCHMED from $21.00 to $20.00 and set a “buy” rating for the company in a report on Tuesday, March 10th. Jefferies Financial Group upgraded HUTCHMED to a “strong-buy” rating in a research report on Monday, January 19th. Wall Street Zen lowered HUTCHMED from a “buy” rating to a “hold” rating in a research note on Saturday, March 7th. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of HUTCHMED in a research report on Thursday, January 22nd. One analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, three have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $16.88.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. State Street Corp increased its holdings in shares of HUTCHMED by 1.2% in the fourth quarter. State Street Corp now owns 321,305 shares of the company’s stock worth $4,283,000 after purchasing an additional 3,801 shares during the last quarter. Renaissance Technologies LLC boosted its stake in HUTCHMED by 3.0% during the fourth quarter. Renaissance Technologies LLC now owns 134,900 shares of the company’s stock valued at $1,798,000 after buying an additional 3,900 shares during the last quarter. Dimensional Fund Advisors LP boosted its stake in HUTCHMED by 157.7% during the fourth quarter. Dimensional Fund Advisors LP now owns 55,969 shares of the company’s stock valued at $746,000 after buying an additional 34,248 shares during the last quarter. M&G PLC grew its holdings in HUTCHMED by 26.7% during the 4th quarter. M&G PLC now owns 259,033 shares of the company’s stock valued at $3,367,000 after buying an additional 54,601 shares in the last quarter. Finally, XY Capital Ltd increased its stake in HUTCHMED by 9.2% in the 4th quarter. XY Capital Ltd now owns 57,610 shares of the company’s stock worth $768,000 after acquiring an additional 4,853 shares during the last quarter. Hedge funds and other institutional investors own 8.82% of the company’s stock.

About HUTCHMED

HUTCHMED (NASDAQ: HCM) is a fully integrated biopharmaceutical company focused on discovering, developing, manufacturing and commercializing targeted therapies and immunotherapies for the treatment of cancer and other diseases. The company leverages in-house capabilities in small-molecule chemistry, biologics engineering and translational medicine to advance candidates through all stages of development. HUTCHMED’s integrated model encompasses early discovery research, clinical development, regulatory filings and commercial launches, enabling seamless progression from laboratory to market.

HUTCHMED’s commercial portfolio includes several in-market oncology therapies approved in China, including fruquintinib for metastatic colorectal cancer, surufatinib for neuroendocrine tumors and savolitinib for non-small cell lung cancer.